PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Bromopride→

Bromopride PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
4093-35-0
Molecular formula
C14H22BrN3O2
Molecular weight
344.25 g/mol
Drug class
Substituted benzamide antiemetic and prokineticdopamine D2-receptor antagonist
Mechanism of action
Antagonises dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, reducing emetic signalling and facilitating upper gastrointestinal motility. Experimental data also report 5-HT4-receptor agonist effects in isolated human atrial tissue; their clinical relevance to its GI use is not established.
Indications / reported uses
  • Nausea and vomiting
  • Functional dyspepsia and selected upper gastrointestinal motility disorders in countries where bromopride is authorised; approved indications and formulations vary by jurisdiction

Sources: Peer-reviewed pharmacology study (2025) · Peer-reviewed clinical review · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Bromopride PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bromopride Permitted Daily Exposure (PDE) report (the Bromopride PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bromopride Occupational Exposure Limit (OEL) report (the Bromopride OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.